Authors: BaoJin Wu WenPeng Li Cheng Qian Wei Ding ZhongWen Zhou Hua Jiang
Publish Date: 2012/11/14
Volume: 34, Issue: 1, Pages: 565-569
Abstract
Recently it was reported that soluble MICB sMICB may impair tumor immunogenicity by reducing natural killer group 2D ligand densities on malignant cells The aim of this study was to elucidate the role of sMICB in melanoma patients In the present study we determined sMICB serum concentration in 125 melanoma patients of different clinical stages of disease compared with 30 healthy controls using an ELISA The correlations between sMICB serum concentration and clinicopathologic variables were analyzed sMICB serum level was significantly elevated P 00005 in melanoma patients mean ± SE = 860 ± 026 ng/ml compared with healthy controls mean ± SE = 627 ± 025 ng/ml Univariate analysis revealed a correlation of sMICB serum concentration with advanced stages of disease P = 0009 Only a slight increase in sMICB serum level P = 0057 could be observed in regard to the tumor burden Patients undergoing current treatment with cytostatics n = 18 revealed a strong increase in sMICB serum level P 00005 whereas treatment with IFNα alone or combined with cytostatics n = 19 showed no change in serum sMICB concentration According to Kaplan–Meier analysis elevated sMICB serum levels were associated with a poor overall and a progressionfree survival Multivariate analysis revealed sMICB serum concentration as an independent predictive factor for progressionfree and overall survival Our results show a prognostic relevance of serum sMICB in melanoma patients indicating that the evaluation of sMICB serum level may be important for the selection of therapeutic strategies
Keywords: